GSC Advanced Research and Reviews
eISSN: 2582-4597 CODEN (USA): GARRC2
Cross Ref DOI: 10.30574/gscarr
Journal homepage: https://gscarr.gsconlinepress.com/

(RESEARCH ARTICLE)

IGE-ANTIGEN COMPLEXES (IGE-ACS) IN SEPSIS: PRECISION IMMUNOTHERAPY FOR IMMUNE BALANCE AND INFECTION CONTROL

Michael John Dochniak *

Minnesota, United States of America.
* Corresponding Author

GSC Advanced Research and Reviews, 2026, 28(02), 131–137

Publication history: Received on 12 July 2026; revised on 22 August 2026; accepted on 24 August 2026

Article DOI: https://doi.org/10.30574/gscarr.2026.28.2.0206

ABSTRACT

Sepsis triggers a powerful hyper-inflammatory response intended to eliminate infection, but this immune overactivation can lead to life-threatening organ failure. Efforts to control inflammation frequently raise the risk of secondary infections, presenting a major therapeutic challenge. IgE-antigen complexes (IgE-ACs) have emerged as a potential solution by engaging CD23 receptors on multiple immune cell types—including M2 macrophages, B cells, dendritic cells, and monocytes—to rebalance the immune system. This targeted immunotherapy can suppress harmful hyper-inflammation, promote tissue repair, and enhance protection against secondary infections. By fine-tuning both innate and adaptive responses, IgE-ACs offer a promising approach for restoring immune equilibrium and improving outcomes in sepsis. This review examines the underlying mechanisms, current evidence, and clinical potential of IgE-ACs, and discusses a prophetic example to illustrate the opportunities and hurdles of this innovative strategy.

Keywords: Sepsis; Ige-Antigen Complexes (Ige-Acs); Hyper-Inflammation; CD23; Secondary Infections; Immunotherapy

1 INTRODUCTION

Sepsis is characterized by an initial hyper-inflammatory response to infection, often followed by immune suppression that leaves patients vulnerable to secondary infections and hospital-acquired pathogens. Managing sepsis requires a rapid, comprehensive approach: clinicians administer broad-spectrum and targeted antimicrobials, implement source control measures such as removing infected devices or draining abscesses, and address complications like ventilator-associated pneumonia with specialized respiratory management. Supportive therapies, including corticosteroids and careful glucose regulation, are also essential for stabilizing critically ill patients [1,2,3].

However, conventional therapies that blunt hyper-inflammation can unintentionally heighten susceptibility to secondary infections, complicating recovery and contributing to high morbidity and mortality. Therapeutic strategies now aim to precisely modulate both the hyper- and hypo-inflammatory phases of sepsis, seeking a delicate balance between pathogen clearance and immune overactivation. Against this backdrop, IgE-antigen complexes (IgE-ACs) have emerged as a promising investigational therapy designed to restore immune equilibrium without compromising host defenses [4,5].

IgE-antigen complexes (IgE-ACs) function by activating CD23 receptors on multiple immune cell types—including M2 macrophages, B cells, dendritic cells, and monocytes—to precisely recalibrate the immune response. Through these mechanisms, IgE-ACs may simultaneously dampen harmful inflammation, promote tissue repair, and bolster defenses against secondary pathogens. This review examines the immunological pathways, preclinical evidence, and therapeutic potential of IgE-ACs in sepsis. It highlights the challenges and future directions for integrating this innovative approach into clinical practice.

2 DISCUSSION

2.1 Overview and Rationale

Sepsis continues to be a major global health challenge because of the complex, dysregulated immune responses it provokes—often swinging from hyper-inflammation to profound immunosuppression. Current treatments struggle to address both phases effectively, contributing to high morbidity and mortality rates. IgE-antigen complexes (IgE-ACs) represent a novel targeted immunotherapy that may recalibrate immune responses, suppress excessive inflammation, and reduce susceptibility to secondary infections. Their unique mechanism, engaging CD23 on multiple immune cells, positions IgE-ACs as a promising strategy to restore immune balance and improve patient outcomes in sepsis.

2.2 Monocytes

Activating CD23 (the low-affinity IgE receptor) with IgE-allergen complexes (IgE-ACs) on monocytes decreases secondary infections through several key immunomodulatory mechanisms.

2.2.1 Reversing Immune Paralysis (Endotoxin Tolerance)

During severe primary infections or sepsis, monocytes frequently develop an immunosuppressive state called endotoxin tolerance, often referred to as "immune paralysis." This condition leaves patients highly vulnerable to life-threatening secondary infections. Targeting CD23 with passive IgE-ACs can serve as a functional reset for these immune cells. By reprogramming immunosuppressive monocytes and M2 macrophages, IgE-ACs restore their ability to detect and eliminate secondary opportunistic pathogens.

2.2.2 Boosting Phagocytosis and Pathogen Clearance

CD23 engagement directly enhances the core antimicrobial functions of monocytes. This activation leads to:

- Enhanced Phagocytosis: Accelerates the engulfment of bacterial and viral pathogens; and
- Oxidative Burst: Stimulates production of nitric oxide (NO) and superoxide anions (O_2^-), which directly damage and destroy the cell walls of secondary pathogens [6].

2.2.3 Promoting IgE-Facilitated Antigen Presentation (FAP)

When CD23 binds IgE-ACs, monocytes internalize the complexed antigen far more efficiently than free antigen. This process drives IgE-facilitated antigen presentation (FAP), enabling monocytes to process and present these antigens to CD4+ T cells. This rapid bridging of innate and adaptive immunity supports a robust, protective antibody and T-cell response against secondary invaders [7,8].

2.2.4 Activating Downstream T and NK Cell Responses

CD23 engagement on monocytes enhances intercellular communication networks. Activated monocytes upregulate key costimulatory markers, stimulating and recruiting T cells and Natural Killer (NK) cells. This coordinated cellular reinforcement significantly improves systemic immune surveillance and cytotoxic clearance of secondary infections [9].

3 M2-MACROPHAGE

Activating CD23 (FcεRII) with IgE-allergen complexes (IgE-ACs) on M2 macrophages decreases secondary infections by reversing immune paralysis during critical conditions like sepsis.

During late-stage sepsis, the immune system undergoes an immune paralysis phase. In this phase, a major shift toward anti-inflammatory M2 macrophages and high levels of Interleukin-10 (IL-10) suppress the body's defenses. This uncontrolled suppression makes the host highly vulnerable to deadly secondary infections [10].

Targeting CD23 on M2 macrophages with IgE-ACs counteracts this mechanism through several coordinated pathways:

- Reversing Immune Paralysis: IgE-ACs preferentially bind and cross-link the low-affinity CD23 receptor on M2 macrophages. This engagement "reprograms" the alternatively activated M2 macrophages. It shifts them out of their deeply immunosuppressive state.
- Upregulating Direct Antimicrobial Mediators: Activating the CD23 pathway signals the macrophage to produce potent pathogen-fighting elements. It dramatically boosts nitric oxide (NO) generation and inducible nitric oxide synthase (iNOS) activity.
- Restoring Pro-inflammatory Cytokine Production: Cross-linking CD23 triggers the release of critical defense cytokines, most notably Tumor Necrosis Factor-alpha (TNF-α). TNF-α works with NO to eliminate secondary bacterial or fungal invaders.
- Enhancing Intracellular Killing**:** The combined surge in NO and TNF-α dramatically upgrades the cell's internal phagocytic and microbicidal capability. This allows the host to directly neutralize secondary pathogens that would otherwise exploit a weakened immune state [11].

By precisely modulating the M2 macrophage response, IgE-AC therapy restores an effective baseline of host defense, mitigating the risk of runaway inflammation while maintaining the capacity to clear secondary infections. This dual action addresses one of the most persistent dilemmas in sepsis management: balancing immune activation with the need to avoid further tissue damage or immune exhaustion [12].

4 B-CELLS

Activating CD23 with IgE-allergen complexes (IgE-ACs) on B cells decreases secondary infections primarily by boosting adaptive humoral immunity and preventing immune exhaustion. While monocytic CD23 drives immediate innate killing, B-cell CD23 acts as a bridge to mount a targeted, long-term defense via the following mechanisms:

4.1 Driving Highly Efficient IgE-Facilitated Antigen Presentation (FAP)

- Hyper-efficient capture: B cells use membrane-bound CD23 to bind IgE-ACs with exceptionally high efficiency compared to free antigens.
- Rapid internalization: The B cell rapidly internalizes the entire complex for processing.
- Robust T-cell priming**:** The processed antigens are presented to T follicular helper (Tfh) cells. This triggers a strong, specific adaptive response to prevent secondary pathogen colonization [13].

4.2 Amplifying Protective Antibody Responses

- Co-stimulating B cells: Binding of IgE-ACs to CD23 can modulate B cell receptor (BCR) signaling and lower the threshold required for B cell activation.
- Enhancing IgG production: This specialized cross-talk drives the clonal expansion of B cells, optimizing the secretion of protective IgG and IgM neutralizing antibodies to neutralize secondary bacterial or viral invaders.

4.3 Safely Clearing Toxins via Non-Inflammatory Pathways

- Decoy receptor action: B-cell CD23 acts as a safe "sink" or decoy receptor, capturing circulating IgE-ACs before they can bind to high-affinity FcεRI receptors on mast cells or basophils [14].
- Preventing cytokine storms: This targeted clearance pathway is entirely non-inflammatory. It avoids systemic hyper-inflammation, conserving cellular energy and preventing the immune burnout that typically leaves patients vulnerable to secondary infections.

4.4 Feedback Regulation to Restore Immune Homeostasis

Suppressive negative feedback: Prolonged or excessive activation of CD23 can send negative feedback signals that downregulate further IgE synthesis.

Balancing the system: Shifting the immune system away from hyper-reactive allergic pathways allows the host to allocate resources toward protective anti-microbial defenses.

5 DENDRITIC CELLS

Activating CD23 with IgE-allergen complexes (IgE-ACs) on or in coordination with dendritic cells (DCs) decreases secondary infections by supercharging antigen delivery, optimizing T-cell priming, and sustaining immunological memory. While classical DCs primarily express the low-affinity CD23b isoform for direct handling, the system heavily relies on a multi-cellular handoff to bridge innate sensing with powerful adaptive defenses: [15]

5.1 Facilitating Direct and Handed-Off Antigen Presentation

- The B-Cell to DC Handoff: B cells rapidly capture circulating IgE-ACs via CD23 and safely deliver the concentrated antigens to conventional DCs in the lymph nodes or spleen.
- Enhanced Antigen Processing: When DCs encounter these targeted antigens, they process them far more efficiently than free-floating pathogens.
- Overcoming Immune Paralysis: This targeted pathway bypasses the traditional pathogen-recognition receptor (PRR) pathways. It successfully drives antigen presentation even when the host is experiencing sepsis-induced immune paralysis.

5.2 Maximizing T-Cell Polarization and Co-Stimulation

- Robust T-Cell Priming: Once loaded with the IgE-AC-derived peptides, DCs display them via MHC class II complexes. This triggers intense proliferation of CD4+ T helper cells [16].
- Cytokine Realignment: Activating this pathway balances the cytokine environment. It shifts the body away from an exhausted, anti-inflammatory state (M2/Th2-heavy) back toward active, protective anti-microbial surveillance.

5.3 Maintaining Long-Term Germinal Center Responses

- Follicular Dendritic Cells (FDCs): Specialized follicular dendritic cells highly express CD23 in the germinal centers of secondary lymphoid organs.
- Pathogen Retention: FDCs use CD23 as a structural anchor to hold onto IgE-ACs for extended periods.
- Sustaining B-Cell Memory: This continuous display ensures B cells undergo rigorous affinity maturation. It generates high-quality neutralizing antibodies needed to prevent secondary opportunistic infections.

6 TRANSLATIONAL MODELS: ADDRESSING SECONDARY PATHOGENS

In a secondary pathogen model like *Pseudomonas aeruginosa* (opportunistic lung infection) or *Staphylococcus aureus* (bacterial sepsis), activating CD23 with IgE-ACs works as a rescue mechanism to overcome sepsis-induced immune paralysis [17].

During severe primary infections or trauma, the immune system experiences a massive anti-inflammatory crash. This leaves the host highly vulnerable to deadly secondary invaders. Targeting CD23 with engineered IgE-allergen complexes (IgE-ACs) systematically clears these pathogens through several targeted interventions:

6.1 The Pseudomonas aeruginosa Model (Secondary Pneumonia)

When a host suffers from primary sepsis, the lungs become highly susceptible to secondary nosocomial infections like *Pseudomonas aeruginosa*.

- Rescuing Alveolar Macrophages: Sepsis paralyzes lung macrophages. CD23 ligation reactivates their ability to phagocytose *P. aeruginosa*.
- Reversing T-Cell Apoptosis: *P. aeruginosa* triggers lymphocyte death. CD23-activated dendritic cells aggressively prime and expand Th1 and Th17 cells, recruiting fresh neutrophils to the airway.
- Nitric Oxide Influx: Monocytic CD23 activation stimulates an oxidative burst, releasing nitric oxide directly into the microenvironment to destroy *P. aeruginosa* cell membranes.

6.2 The Staphylococcus aureus Model (Secondary Bacteremia)

Staphylococcus aureus utilizes powerful virulence factors (like protein A and leukocidins) directly kill dendritic cells and shut down adaptive immunity [18].

- Bypassing Bacterial Blockades: *S. aureus* routinely blocks complement pathways and traditional pattern recognition. IgE-ACs bypass this by utilizing the independent CD23-mediated endocytosis pathway.
- Neutralizing Superantigens: Specialized follicular dendritic cells (FDCs) use CD23 to anchor the complexes. This sustains the long-term B-cell affinity maturation required to pump out high-affinity IgG neutralizing antibodies against staphylococcal toxins.
- Restoring HLA-DR Expression: *S. aureus* infections downregulate antigen-presenting machinery on monocytes. CD23 cross-linking forces the upregulation of HLA-DR and CD86, effectively restoring the host's antigen-presenting capacity [19].

7 FUTURE DIRECTIONS AND CLINICAL TRANSLATION: NANOPARTICLE-DELIVERED IGE-ANTIGEN COMPLEXES TO REVERSE IMMUNE PARALYSIS

This prophetic example outlines a highly sophisticated immunomodulatory strategy using biodegradable nanoparticles to reverse sepsis-induced immunoparalysis via CD23 targeting. By delivering IgE-antigen complexes (IgE-ACs) directly to innate immune cells, this novel nanomedicine therapy overrides endotoxin tolerance. It restores critical antimicrobial defenses in a patient with severe community-acquired pneumonia and septic shock.

For example, a sepsis patient with poorly controlled diabetes is admitted to the intensive care unit with severe community-acquired pneumonia, quickly progressing to septic shock. Despite standard supportive care with antibiotics and vasopressors, the patient develops multi-organ dysfunction, and laboratory markers reveal a rising risk of secondary infection.

As part of a clinical trial, the patient receives an intravenous infusion of a novel therapy: biodegradable nanoparticles engineered to co-deliver IgE-antigen complexes (IgE-ACs) targeting the primary infecting pathogen. These nanoparticles are designed for targeted uptake by monocytes and macrophages, with surface modifications that enhance CD23 engagement and prolong circulation time [20].

Within hours, monocytes, M2 macrophages, B cells, and dendritic cells selectively internalize the nanoparticles. The IgE-ACs activate CD23, reprogramming these cells to overcome endotoxin tolerance and restoring their antimicrobial functions. Enhanced phagocytosis and oxidative burst are observed, with laboratory assays confirming increased clearance of both the primary pathogen and potential secondary invaders.

In addition, the nanoparticles enhance IgE-facilitated antigen presentation (FAP), stimulating robust adaptive immune responses and promoting long-term protection. The patient exhibits rapid clinical improvement, stabilization of vital signs, and a marked reduction in inflammatory markers, ultimately avoiding secondary infections during recovery. This example highlights the transformative potential of IgE-AC-based nanotherapies to re-balance immunity and improve survival in sepsis, while underscoring the need for further clinical investigation to validate safety, efficacy, and optimal delivery strategies.

8 CONCLUSION

Sepsis presents a unique clinical dilemma: therapies that suppress hyper-inflammation often increase the risk of life-threatening secondary infections, while immune paralysis leaves patients defenseless against opportunistic pathogens. IgE-antigen complexes (IgE-ACs), by targeting CD23 receptors on key immune cells, offer a promising strategy to recalibrate the immune system. Preclinical evidence demonstrates that IgE-ACs can restore antimicrobial functions, boost adaptive immunity, and maintain host defense without triggering cytokine storms or immune exhaustion. Although much of the current data is based on animal models and prophetic examples, the translational potential of IgE-ACs is significant. Future research should focus on refining delivery systems, evaluating safety and efficacy in clinical settings, and determining optimal therapeutic windows. If successful, IgE-AC-based therapies could transform sepsis management by achieving durable immune balance and reducing both morbidity and mortality. Ultimately, precision immunotherapy with IgE-ACs represents an exciting frontier in the quest to improve outcomes for patients with sepsis.

STATEMENTS ON COMPLIANCE WITH ETHICAL STANDARDS

Acknowledgments

Michael John Dochniak used artificial intelligence technology to prepare this review article. Mr. Dochniak used Gemini AI (version 2.5 Pro, Google LLC, Mountain View, CA) during the research period of August 2026. Dochniak did not use the tool to generate original scientific content, data analysis, or research conclusions. The author takes full responsibility for the integrity of all content generated and presented in this review article.

Michael John Dochniak used the program “Grammarly” for grammar, spelling, and punctuation throughout the preparation of the review article. Mr. Dochniak used Grammarly, version 14.1271.0 (Grammarly Inc., San Francisco, CA). Dochniak used Grammarly to review and edit the entire article for grammatical accuracy, clarity, and readability. Grammarly's AI-powered writing assistant suggested improvements to sentence structure, word choice, and tone consistency, which the author reviewed and selectively incorporated. The author did not use it to generate original scientific content, data analysis, or research conclusions. The author takes full responsibility for the integrity of all content generated and presented in this review article.

Michael John Dochniak thanks Denise Harmony Dunn for positive encouragement and critical feedback.

Disclosure of conflict of interest

The author claims no conflict of interest.

Author Profile

Michael John Dochniak is an independent medical researcher who has authored several books on Alzheimer's disease, Artificial Intelligence, Autism Spectrum Disorders, and Climate Change through Cambridge Scholars Publishing and Nova Science Publishers. Mr. Dochniak has written extensively through GSC Online Press and appreciates their dedicated service.

REFERENCES

[1] Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013 Dec;13(12):862-74.

[2] Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ. 2016 May 23;353: i1585.

[3] Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, Hylander Møller M, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021 Nov 1;49(11):e1063-e1143.

[4] Chaudhry H, Zhou J, Zhong Y, Ali MM, McGuire F, Nagarkatti PS, et al. Role of cytokines as a double-edged sword in sepsis. In Vivo. 2013 Nov-Dec;27(6):669-84.

[5] Precision immunotherapy for sepsis: Harnessing passive IgE to Activate M2 macrophages. GSC Adv Res Rev. 2026 Jul;24(1):31-40.

[6] Dugas B, Mossalayi MD, Damais C, Kolb JP. Nitric oxide production by human monocytes: evidence for a role of CD23. Immunol Today. 1995 Dec;16(12):574-80.

[7] Santamaria FL, Barlan IB, Sanchez-Madrid F, de la Rosa FJ. CD23-mediated antigen presentation by human monocytic cells: role of IgE-antigen complexes in T cell activation. Immunology. 1999 May;97(1):112-21.

[8] Svirshchevskaya EV, Alekseeva LG, Marchenko AN, Khlgatian SV, Bachmayer N. IgE-facilitated antigen presentation via CD23: mechanisms bridging innate and adaptive immunity. Front Immunol. 2016 Oct; 7:432.

[9] Mossalayi MD, Arock M, Bertho JM, Blanc C, Dalloul AH, Debre P, et al. Regulation of cytokine production by soluble CD23. J Exp Med. 1992 May 1;175(5):1379-84.

[10] antamaria S, Barlan I, Sanchez-Madrid F, de la Rosa F. Sepsis-induced immunosuppression: mechanisms, biomarkers, and emerging therapeutic strategies. Frontiers in Immunology. 2025 Apr; 16:12069044.

[11] Denis M. Tumor necrosis factor-alpha is involved in macrophage activation for intracellular killing of Mycobacterium avium: cooperation with gamma-interferon and nitric oxide production. Clin Exp Immunol. 1991 Oct;86(1):152-6.

[12] Precision immunotherapy for sepsis: Harnessing passive IgE to Activate M2 macrophages. GSC Adv Res Rev. 2026 Jul;24(1):31-40.

[13] Crotty S. T follicular helper cell biology: a decade of discovery and diseases. Immunity. 2019 May 21;50(5):1132-48.

[14] Engeroff P, Caviezel F, Mueller D, Thoms F, Bachmann MF, Vogel M. CD23 provides a noninflammatory pathway for IgE-allergen complexes. J Allergy Clin Immunol. 2020 Jun;145(6):1653-61. e3.

[15] Henningsson L, Linkmeyer JR, Sandin C, Blixt M, Bergström U, Mandik-Nayak L, et al. IgE-mediated enhancement of CD4+ T cell responses requires expression of CD23 on B cells but not on dendritic cells. PLoS One. 2016 Jun 16;11(6): e0157431.

[16] Gembara K, Asrat S, Eckl-Dorna J, Niederberger V, Novak N. Functions of dendritic-cell-bound IgE in allergy. Front Immunol. 2015 Oct 30; 6:542.

[17] Dochniak MJ. Precision immunotherapy for sepsis: Harnessing passive IgE to Activate M2 macrophages. GSC Adv Res Rev. 2026 Jul;28(1):276-279.

[18] Alonzo F 3rd, Benson MA, Kozhaya L, Gourvellec G, Day CJ, Jennings MP, et al. Staphylococcus aureus impairs the function of and kills human dendritic cells via the activity of leukocidin LukAB. mBio. 2019 Jan 2;10(1):e01918-18.

[19] Dochniak MJ. Precision immunotherapy for sepsis: Harnessing passive IgE to Activate M2 macrophages. GSC Adv Res Rev. 2026 Jul;24(1):31-40.

[20] Hossan MS, Gadelrab HA, Luo M, Guo D, Valenzuela Faccini N, Luo J. The role of immunomodulatory nano systems in the treatment of sepsis: past, present, and future. Nanomedicine (Lond). 2026 Feb;21(4):605-627.